¹⁷⁷Lu-LNC1004 is a new radiolabeled drug targeting fibroblast activation protein (FAP) developed by the company Yantai LNC Biotechnology, Singapore. The molecule is a fibroblast activation protein inhibitor (FAPi) modified with Evans blue (EB) which will be used to treat patients selected on the basis of the Tracer ⁶⁸Ga-FAPI-46 (companion diagnostic agent). A Phase I trial was initiated in April 2023.

Target/Mechanism: Fibroblasts

Carrier/Ligand: FAPI

Radiation Type: beta electrons (β^–)